Adjuvant pembrolizumab (Keytruda) continued to improve disease-free survival (DFS) and overall survival (OS) vs placebo with benefits consistent in the overall population and across prespecified subgroups of patients with clear cell renal cell…
Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence
